Reynaldo Homen

Reynaldo Homen

Auto-generated profile, based on publicly available information

Reynaldo Homen

Servicio de Enfermedades Infecciosas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC) Hospital Clínico San Carlos Madrid Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IAInés Armenteros-Yeguas
Inés Armenteros-Yeguas
RHReynaldo Homen
Reynaldo Homen
AVAdrián Valls
Adrián Valls
LDLaura Dans
Laura Dans
EOEva Orviz
Eva Orviz
VEVicente Estrada
Vicente Estrada
Background: Mpox is a viral disease caused by an orthopoxvirus called monkeypox virus. It experienced a significant increase in cases in 2022 worldwide, mostly with sexual transmission. The possibility of hidden circulation of this infection among asymptomatic individuals remains unclear. Methods: This is a multi-centre, observational cross-sectional study conducted in a sexually transmitted infections (STIs) clinic in its referral hospital between July and October 2023 in Madrid, Spain. Pharyngeal and rectal swab samples were collected from each participant and processed to detect bacterial STIs and mpox. Socio-demographic, clinical and behavioural data were collected, and a descriptive analysis was performed. Results: A total of 343 asymptomatic participants were included. The prevalence of asymptomatic mpox infection was 0.3% (n = 1) and the only positive case developed symptoms shortly after sampling, ruling out a fully asymptomatic infection. The percentage of vaccinated individuals was 36.1%. 13.2% had previously contracted mpox. Other STIs were detected in 21.6% of participants. Conclusions: Although routine screening for asymptomatic bacterial sexually transmitted infections is strongly recommended in at-risk individuals, testing for asymptomatic mpox should be evaluated based on the specific context and population. Additionally, the ongoing cases of mpox in Spain are likely not related to the presence of asymptomatic carriers.

25 November 2025 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
JFJose‐Reynaldo Homen Fernandez
Jose‐Reynaldo Homen Fernandez
IAInés Armenteros
Inés Armenteros
ACAdrián Valls Carbó
Adrián Valls Carbó
JBJulia Barrado
Julia Barrado
COCarolina Olmos‐Mata
Carolina Olmos‐Mata
VEVicente Estrada
Vicente Estrada
Background: Lower respiratory tract infections (LRTIs) impose a significant global burden, with over 400 million cases annually. This study compares the clinical features of adults hospitalized with respiratory syncytial virus (RSV) and COVID‐19, two viral pathogens with similar presentations but differing epidemiology. Methods: This cross‐sectional study analyzed 100 adult cases with PCR‐confirmed RSV or COVID‐19, admitted to the hospital from January 2022 to March 2023. Data on clinical, sociodemographic, radiological, treatment, and laboratory variables were extracted from records. Results: Both cohorts consisted of elderly patients (> 70 years) with multiple comorbidities. Notably, the RSV group had a higher prevalence of CHF (24% vs. 10%, p = 0.014) and COPD (29% vs. 9%, p = 0.001). Radiologically, 51% of RSV patients had normal findings, whereas 48% of COVID‐19 patients exhibited bilateral pneumonia ( p = 0.001). Antimicrobial treatment was administered to 75% of RSV patients compared to 41% of COVID‐19 patients ( p < 0.001). RSV patients had marginally higher leukocyte and neutrophil counts, while COVID‐19 patients showed significantly elevated CRP, ferritin, LDH, ALT, and potassium levels. Conclusions: Distinct profiles were identified between hospitalized RSV and COVID‐19 patients. RSV patients, mostly older with CHF and COPD, were more likely to receive antibiotics, possibly reflecting the lack of targeted therapies. In contrast, COVID‐19 patients exhibited higher inflammation and lung involvement. These findings highlight the need to refine treatment protocols, enhance antimicrobial stewardship, and develop specific RSV therapies alongside preventive strategies for high‐risk groups.

11 February 2025
Verified
Preprint
Open access
IAInés Armenteros-Yeguas
Inés Armenteros-Yeguas
RHReynaldo Homen
Reynaldo Homen
AVAdrián Valls
Adrián Valls
LDLaura Dans
Laura Dans
EOEva Orviz
Eva Orviz
VEVicente Estrada
Vicente Estrada
Background: Mpox is a viral disease caused by an orthopoxvirus called monkeypox virus. It experienced a significant increase in cases in 2022 worldwide, mostly with sexual transmission. The possibility of hidden circulation of this infection among asymptomatic individuals remains unclear. Methods: This is a multi-centre, observational cross-sectional study conducted in a sexually transmitted infections (STIs) clinic in its referral hospital between July and October 2023 in Madrid, Spain. Pharyngeal and rectal swab samples were collected from each participant and processed to detect bacterial STIs and mpox. Socio-demographic, clinical and behavioural data were collected and a descriptive analysis was performed. Results: A total of 343 asymptomatic participants were included. The prevalence of asymptomatic mpox infection was 0.3% (n=1) and the only positive case developed symptoms shortly after sampling, ruling out a fully asymptomatic infection. The percentage of vaccinated individuals was 36.1%. 13.2% had previously contracted mpox. Other STIs were detected in 21.6% of participants. Conclusions: Although there is an asymptomatic period before symptoms in which individuals could transmit mpox infection, testing for asymptomatic individuals at risk of STIs is not a cost-effective approach. Additionally, the ongoing cases of mpox in Spain are likely not related to the presence of asymptomatic carriers.